
News|Articles|December 10, 2012
FDA expands Zytiga's use for late-stage prostate cancer
FDA expanded the approved use of abiraterone acetate (Zytiga, Jannsen Bioech) to treat men with late-stage castration-resistant prostate cancer prior to receiving chemotherapy.
Advertisement
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Glutamate levels associated with psychosis onset in treatment-naive patients, study finds
2
A jump in shingles after first Shingrix dose but the risk is transient, study finds
3
More evidence that the shingles vaccine may have protective effects beyond preventing shingles
4
How California is rewriting the PBM playbook
5




















































